| 2026 |
| 05/22 | 4,085 | 4,145 | 4,085 | 4,105 | +0.12% | 66,400 | 1811億9359万 | -0.19% |
| 05/21 | 4,155 | 4,170 | 4,095 | 4,100 | -1.32% | 105,000 | 1809億7289万 | -0.39% |
| 05/20 | 4,195 | 4,230 | 4,130 | 4,155 | -0.24% | 120,800 | 1834億57万 | +0.9% |
| 05/19 | 4,175 | 4,190 | 4,140 | 4,165 | +0.12% | 112,800 | 1838億4197万 | +1.09% |
| 05/18 | 4,125 | 4,175 | 4,090 | 4,160 | +0.24% | 200,100 | 1836億2127万 | +0.92% |
| 05/15 | （IR情報）15:30 脈管奇形治療剤「KP-001」の製造販売承認申請について |
| 05/15 | 4,230 | 4,230 | 4,115 | 4,150 | -1.78% | 176,800 | 1831億7987万 | +0.61% |
| 05/14 | 3,980 | 4,235 | 3,905 | 4,225 | +5.36% | 262,700 | 1864億9035万 | +2.35% |
| 05/13 | （IR情報）15:30 資本コストや株価を意識した経営の実現に向けた対応について(アップデート) |
| 05/13 | （IR情報）15:30 個別業績の前期実績値との差異に関するお知らせ |
| 05/13 | （IR情報）15:30 2026年3月期決算短信〔日本基準〕(連結) |
| 05/13 | （IR情報）15:30 ダイト承継2製品に関する販売提携契約締結について |
| 05/13 | 4,045 | 4,060 | 4,010 | 4,010 | -1.11% | 115,800 | 1770億31万 | -2.81% |
| 05/12 | 4,075 | 4,100 | 4,025 | 4,055 | -0.49% | 100,200 | 1789億8660万 | -1.91% |
| 05/11 | 4,005 | 4,085 | 4,005 | 4,075 | +1.12% | 178,500 | 1798億6939万 | -1.59% |
| 05/08 | 4,060 | 4,090 | 3,990 | 4,030 | -0.49% | 187,600 | 1778億8311万 | -2.75% |
| 05/07 | 4,075 | 4,105 | 4,010 | 4,050 | -0.61% | 156,100 | 1787億6590万 | -2.36% |
| 05/01 | 4,050 | 4,075 | 4,015 | 4,075 | -0.12% | 106,800 | 1798億6939万 | -1.95% |
| 04/30 | 4,055 | 4,095 | 4,030 | 4,080 | +0.49% | 137,600 | 1800億9009万 | -1.97% |
| 04/28 | 4,075 | 4,090 | 4,015 | 4,060 | -0.37% | 128,900 | 1792億730万 | -2.54% |
| 04/27 | 4,090 | 4,110 | 4,050 | 4,075 | -0.97% | 151,600 | 1798億6939万 | -2.28% |
| 04/24 | 4,150 | 4,175 | 4,095 | 4,115 | -1.2% | 159,900 | 1816億3498万 | -1.37% |
| 04/23 | 4,020 | 4,175 | 4,020 | 4,165 | +3.74% | 216,400 | 1838億4197万 | -0.26% |
| 04/22 | （IR情報）15:30 Johnson&Johnsonとのライセンス契約に係るマイルストン達成およびマイルストン収入の受領等に伴う2026年3月期連結業績予想修正に関するお知らせ |
| 04/22 | 4,085 | 4,095 | 4,010 | 4,015 | -1.71% | 76,800 | 1772億2101万 | -3.97% |
| 04/21 | 4,135 | 4,165 | 4,070 | 4,085 | -1.33% | 81,800 | 1803億1079万 | -2.53% |
| 04/20 | 4,180 | 4,185 | 4,130 | 4,140 | -0.84% | 80,100 | 1827億3848万 | -1.33% |
| 04/17 | 4,160 | 4,195 | 4,150 | 4,175 | -0.95% | 68,100 | 1842億8337万 | -0.57% |
| 04/16 | 4,200 | 4,215 | 4,165 | 4,215 | +0.36% | 122,800 | 1860億4896万 | +0.36% |
| 04/15 | 4,190 | 4,200 | 4,155 | 4,200 | +1.45% | 74,000 | 1853億8686万 | -0.05% |
| 04/14 | 4,200 | 4,210 | 4,120 | 4,140 | -1.31% | 86,100 | 1827億3848万 | -1.59% |
| 04/13 | 4,145 | 4,200 | 4,140 | 4,195 | +1.21% | 96,500 | 1851億6616万 | -0.4% |
| 04/10 | 4,195 | 4,210 | 4,120 | 4,145 | -1.07% | 76,300 | 1829億5918万 | -1.66% |
| 04/09 | 4,220 | 4,240 | 4,190 | 4,190 | -0.71% | 61,900 | 1849億4546万 | -0.71% |
| 04/08 | 4,280 | 4,285 | 4,215 | 4,220 | -0.24% | 102,200 | 1862億6966万 | -0.05% |
| 04/07 | 4,225 | 4,245 | 4,210 | 4,230 | +0.12% | 58,000 | 1867億1105万 | +0.12% |
| 04/06 | 4,210 | 4,245 | 4,200 | 4,225 | +0.72% | 74,300 | 1864億9035万 | -0.14% |
| 04/03 | 4,190 | 4,215 | 4,160 | 4,195 | -0.24% | 79,900 | 1851億6616万 | -1.04% |
| 04/02 | 4,235 | 4,265 | 4,185 | 4,205 | -0.59% | 126,500 | 1856億756万 | -0.94% |
| 04/01 | 4,185 | 4,230 | 4,160 | 4,230 | +2.17% | 91,600 | 1867億1105万 | -0.52% |
| 03/31 | 4,140 | 4,160 | 4,115 | 4,140 | 0% | 98,500 | 1827億3848万 | -2.7% |
| 03/30 | 4,090 | 4,140 | 4,065 | 4,140 | -2.7% | 128,300 | 1827億3848万 | -2.82% |
| 03/27 | （IR情報）16:00 役員人事のお知らせ |
| 03/27 | 4,240 | 4,270 | 4,210 | 4,255 | +0.83% | 130,100 | 1878億1455万 | -0.26% |
| 03/26 | 4,215 | 4,245 | 4,190 | 4,220 | +1.08% | 84,400 | 1862億6966万 | -1.08% |
| 03/25 | 4,185 | 4,225 | 4,175 | 4,175 | +0.24% | 110,900 | 1842億8337万 | -2.11% |
| 03/24 | 4,155 | 4,180 | 4,145 | 4,165 | +1.34% | 91,300 | 1838億4197万 | -2.39% |
| 03/23 | 4,200 | 4,200 | 4,100 | 4,110 | -2.61% | 139,300 | 1814億1429万 | -3.75% |
| 03/19 | 4,260 | 4,280 | 4,220 | 4,220 | -1.75% | 229,700 | 1862億6966万 | -1.26% |
| 03/18 | （IR情報）10:00 遺伝性血管性浮腫（HAE）急性発作治療用血漿カリクレイン阻害薬「エクテリー錠300mg」の薬価基準収載および新発売について |
| 03/18 | 4,250 | 4,295 | 4,250 | 4,295 | +0.59% | 111,400 | 1895億8014万 | +0.49% |
| 03/17 | 4,220 | 4,285 | 4,220 | 4,270 | +1.55% | 86,800 | 1884億7664万 | 0% |
| 03/16 | 4,205 | 4,225 | 4,195 | 4,205 | -0.12% | 93,100 | 1856億756万 | -1.38% |
| 03/13 | 4,195 | 4,240 | 4,195 | 4,210 | 0% | 111,400 | 1858億2826万 | -1.2% |
| 03/12 | 4,250 | 4,260 | 4,200 | 4,210 | -1.29% | 122,600 | 1858億2826万 | -1.1% |
| 03/11 | 4,325 | 4,350 | 4,265 | 4,265 | -1.04% | 156,400 | 1882億5594万 | +0.26% |
| 03/10 | 4,320 | 4,335 | 4,280 | 4,310 | +1.06% | 128,000 | 1902億4223万 | +1.48% |
| 03/09 | 4,215 | 4,290 | 4,180 | 4,265 | -0.47% | 185,600 | 1882億5594万 | +0.66% |
| 03/06 | 4,220 | 4,310 | 4,205 | 4,285 | +0.47% | 143,900 | 1891億3874万 | +1.35% |
| 03/05 | 4,315 | 4,325 | 4,260 | 4,265 | +0.47% | 163,800 | 1882億5594万 | +1.11% |
| 03/04 | 4,240 | 4,250 | 4,175 | 4,245 | -0.93% | 230,600 | 1873億7315万 | +0.76% |
| 03/03 | 4,350 | 4,370 | 4,285 | 4,285 | -2.28% | 173,800 | 1891億3874万 | +1.78% |
| 03/02 | 4,420 | 4,420 | 4,350 | 4,385 | -1.13% | 171,100 | 1935億5271万 | +4.21% |
| 02/27 | 4,315 | 4,445 | 4,305 | 4,435 | +2.42% | 205,100 | 1957億5970万 | +5.6% |
| 02/26 | 4,360 | 4,365 | 4,310 | 4,330 | -1.03% | 146,200 | 1911億2503万 | +3.39% |
| 02/25 | 4,330 | 4,390 | 4,305 | 4,375 | +1.63% | 164,100 | 1931億1131万 | +4.64% |
| 02/24 | 4,270 | 4,330 | 4,260 | 4,305 | +0.82% | 167,400 | 1900億2153万 | +3.19% |
| 02/20 | 4,240 | 4,285 | 4,240 | 4,270 | -0.47% | 74,200 | 1884億7664万 | +2.55% |
| 02/19 | 4,225 | 4,290 | 4,195 | 4,290 | +0.94% | 150,900 | 1893億5944万 | +3.22% |
| 02/18 | 4,245 | 4,260 | 4,225 | 4,250 | +0.95% | 77,000 | 1875億9385万 | +2.41% |
| 02/17 | 4,230 | 4,235 | 4,195 | 4,210 | -0.47% | 86,300 | 1858億2826万 | +1.62% |
| 02/17 | （空売り報告）Citigroup Global Markets Limited 197,743株（0.44%）-0.13%義務消失 |
| 02/16 | 4,235 | 4,270 | 4,190 | 4,230 | +0.12% | 141,100 | 1867億1105万 | +2.22% |
| 02/13 | 4,230 | 4,235 | 4,180 | 4,225 | +0.12% | 102,700 | 1864億9035万 | +2.25% |
| 02/12 | 4,215 | 4,255 | 4,205 | 4,220 | +0.12% | 178,500 | 1862億6966万 | +2.28% |
| 02/12 | （空売り報告）Citigroup Global Markets Limited 252,643株（0.57%）-0.11% |
| 02/10 | 4,170 | 4,235 | 4,170 | 4,215 | +0.72% | 141,800 | 1860億4896万 | +2.41% |
| 02/09 | 4,210 | 4,225 | 4,160 | 4,185 | +1.45% | 270,800 | 1847億2477万 | +1.87% |
| 02/09 | （空売り報告）Citigroup Global Markets Limited 301,943株（0.68%）-0.02% |
| 02/06 | （IR情報）15:30 2026年3月期第3四半期決算短信〔日本基準〕(連結) |
| 02/06 | 4,110 | 4,140 | 4,095 | 4,125 | -0.12% | 122,800 | 1820億7638万 | +0.59% |
| 02/06 | （空売り報告）Citigroup Global Markets Limited 312,743株（0.7%）+0.03% |
| 02/05 | 4,150 | 4,165 | 4,130 | 4,130 | +0.24% | 151,400 | 1822億9708万 | +0.81% |
| 02/05 | （空売り報告）Citigroup Global Markets Limited 299,443株（0.67%）+0.11% |
| 02/04 | 4,120 | 4,150 | 4,110 | 4,120 | -0.24% | 106,800 | 1818億5568万 | +0.59% |
| 02/04 | （空売り報告）Citigroup Global Markets Limited 249,443株（0.56%）新規 |
| 02/03 | 4,105 | 4,145 | 4,080 | 4,130 | +1.23% | 125,900 | 1822億9708万 | +0.81% |
| 02/02 | 4,125 | 4,130 | 4,080 | 4,080 | +0.37% | 135,400 | 1800億9009万 | -0.37% |
| 01/30 | 4,080 | 4,085 | 4,040 | 4,065 | +0.49% | 105,400 | 1794億2800万 | -0.73% |
| 01/29 | 4,015 | 4,065 | 3,990 | 4,045 | +0.12% | 221,700 | 1785億4520万 | -1.2% |
| 01/28 | 4,100 | 4,105 | 4,040 | 4,040 | -2.42% | 181,500 | 1783億2450万 | -1.29% |
| 01/27 | 4,120 | 4,170 | 4,095 | 4,140 | -0.72% | 154,100 | 1827億3848万 | +1.1% |
| 01/26 | 4,195 | 4,200 | 4,145 | 4,170 | -1.3% | 128,000 | 1840億6267万 | +1.96% |
| 01/23 | 4,200 | 4,240 | 4,180 | 4,225 | +0.6% | 114,200 | 1864億9035万 | +3.45% |
| 01/22 | 4,140 | 4,205 | 4,140 | 4,200 | +1.57% | 145,100 | 1853億8686万 | +3.04% |
| 01/21 | 4,135 | 4,160 | 4,105 | 4,135 | -0.36% | 114,100 | 1825億1778万 | +1.72% |
| 01/20 | 4,120 | 4,165 | 4,100 | 4,150 | 0% | 109,700 | 1831億7987万 | +2.32% |
| 01/19 | （IR情報）9:30 原発性腋窩多汗症治療剤「ECCLOCK」の韓国における発売について |
| 01/19 | 4,090 | 4,155 | 4,090 | 4,150 | +1.47% | 150,000 | 1831億7987万 | +2.49% |
| 01/16 | 4,080 | 4,120 | 4,055 | 4,090 | 0% | 123,600 | 1805億3149万 | +1.29% |
| 01/15 | 4,135 | 4,140 | 4,085 | 4,090 | -0.73% | 110,400 | 1805億3149万 | +1.54% |
| 01/14 | 4,080 | 4,135 | 4,080 | 4,120 | +0.98% | 133,200 | 1818億5568万 | +2.62% |
| 01/13 | 4,130 | 4,130 | 4,070 | 4,080 | -0.49% | 152,700 | 1800億9009万 | +1.95% |
| 01/09 | 4,070 | 4,115 | 4,070 | 4,100 | +0.61% | 106,400 | 1809億7289万 | +2.78% |
| 01/08 | 4,080 | 4,120 | 4,050 | 4,075 | 0% | 169,600 | 1798億6939万 | +2.44% |
| 01/07 | 4,010 | 4,080 | 3,990 | 4,075 | +2.64% | 221,700 | 1798億6939万 | +2.7% |
| 01/07 | （IR情報）8:30 TYK2阻害剤「ESK-001」の 第III相臨床試験「ONWARD1」及び「ONWARD2」結果速報に関する アルミス社の発表について |
| 01/06 | 4,000 | 4,015 | 3,965 | 3,970 | -1.12% | 177,900 | 1752億3472万 | +0.25% |
| 01/05 | 3,995 | 4,030 | 3,960 | 4,015 | 0% | 202,600 | 1772億2101万 | +1.54% |
| 2025 |
| 12/30 | 4,005 | 4,060 | 4,000 | 4,015 | +0.25% | 199,200 | 1772億2101万 | +1.72% |
| 12/29 | 4,060 | 4,090 | 3,975 | 4,005 | -2.91% | 379,100 | 1767億7961万 | +1.7% |
| 12/26 | 4,115 | 4,135 | 4,105 | 4,125 | 0% | 73,100 | 1820億7638万 | +4.99% |
| 12/25 | 4,085 | 4,135 | 4,085 | 4,125 | +0.98% | 71,600 | 1820億7638万 | +5.44% |
| 12/24 | 4,100 | 4,150 | 4,080 | 4,085 | -0.12% | 131,200 | 1803億1079万 | +4.9% |
| 12/23 | 4,050 | 4,095 | 4,045 | 4,090 | +1.36% | 105,600 | 1805億3149万 | +5.47% |
| 12/22 | （IR情報）15:30 遺伝性血管性浮腫（HAE）急性発作治療用血漿カリクレイン阻害薬「エクテリー錠300mg」の国内製造販売承認取得について |
| 12/22 | 4,045 | 4,055 | 4,010 | 4,035 | +0.37% | 145,200 | 1781億381万 | +4.51% |
| 12/19 | 4,050 | 4,060 | 4,015 | 4,020 | -1.47% | 145,100 | 1774億4171万 | +4.52% |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
